# Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

> **NCT00003850** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 47 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00003850
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-04
- **Primary completion:** 2003-06
- **Final completion:** —
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2013-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003850, "Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00003850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*